Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Extended-release methylphenidate (Ritalin LA).

Katherine A Lyseng-Williamson1, Gillian M Keating

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|October 17, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer.

Drugs·2020
Same author

Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer.

Drugs·2020
Same author

Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features.

Clinical drug investigation·2020
Same author

Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features.

Clinical drug investigation·2019
Same author

Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features.

Clinical drug investigation·2019
Same author

Correction to: Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2019
Same journal

Ecnoglutide: First Approvals.

Drugs·2026
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
See all related articles

Extended-release methylphenidate (Ritalin LA) offers a new once-daily treatment option for attention deficit/hyperactivity disorder (ADHD). Clinical trials show it effectively improves ADHD symptoms in children with a safety profile similar to immediate-release formulations.

Area of Science:

  • Pharmacology and Therapeutics
  • Neuroscience
  • Pediatric Psychiatry

Background:

  • Attention deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder.
  • Methylphenidate is a central nervous system stimulant used to manage ADHD symptoms.
  • Existing formulations often require multiple daily doses, impacting treatment adherence.

Purpose of the Study:

  • To evaluate the pharmacokinetics and efficacy of an extended-release formulation of methylphenidate (Ritalin LA).
  • To assess the safety and tolerability of Ritalin LA in children with ADHD.
  • To determine if Ritalin LA permits convenient once-daily administration for ADHD management.

Main Methods:

  • Pharmacokinetic analysis in children with ADHD and healthy adults following a single 20mg dose.

Related Experiment Videos

  • A 2-week randomized, double-blind, placebo-controlled trial in 134 children (aged 6-12 years) with ADHD.
  • Assessment of symptom improvement using Ritalin LA (10-40mg once daily) compared to placebo.

    • Main Results:

    • Extended-release methylphenidate demonstrated two distinct peak plasma concentrations approximately 4 hours apart, mimicking two doses of immediate-release methylphenidate.
    • Ritalin LA significantly improved both inattention and hyperactivity symptoms compared to placebo in children with ADHD.
    • The formulation was effective in children with combined-type or predominantly inattentive-type ADHD.

    Conclusions:

    • Extended-release methylphenidate (Ritalin LA) provides a viable once-daily dosing option for ADHD treatment.
    • The pharmacokinetic profile supports convenient administration and sustained symptom control.
    • Safety and tolerability were consistent with immediate-release methylphenidate, suggesting a favorable profile for pediatric use.